Identification of oleanolic acid for glucose-6-phosphate dehydrogenase-related disorders including Bag3opathy
Overview
HKBU has developed a technology relates to the identification and therapeutic potential of oleanolic acid and plant extracts, particularly Chaenomelis Fructus, for treating glucose-6-phosphate dehydrogenase (G6PD) deregulated disorders, including Bag3opathy, amyotrophic lateral sclerosis (ALS), Huntington disease, Parkinson disease, and Alzheimer disease.
Commercialisation opportunities
Technology licensing
Problem addressed
This invention addresses the issue for lack of effective treatments for glucose-6-phosphate dehydrogenase (G6PD)-deregulated disorders, including BAG3opathy and neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Huntington disease, Parkinson disease, and Alzheimer disease.
Innovation
- Oleanolic acid and plant extracts, such as Chaenomelis Fructus, are proposed for treating G6PD deregulated disorders, including Bag3opathy, ALS, Huntington disease, Parkinson disease, and Alzheimer disease.
- The therapeutic effects of oleanolic acid are attributed to its activation of Nrf2, which regulates G6PD expression and protects against oxidative stress.
Key impact
- Utilizes oleanolic acid from widely available plants (e.g., Chaenomelis Fructus), avoiding synthetic drug development challenges.
- Covers prodrug derivatives and pharmaceutical compositions for oral administration.
Award
- Bronze Medal at the “2025 Geneva International Exhibition of Inventions”
Application
- Oleanolic acid and its plant extracts can be developed as novel therapies for G6PD-deregulated disorders.
Patent
- US Patent No.: US 20240148751 A1
